论文部分内容阅读
冠心病的发病机制与脂质浸润、炎症损伤、内皮细胞功能障碍等密切相关.即使在无糖尿病的冠心病患者中,胰岛素抵抗也是普遍存在的,并且参与冠心病发生发展的各个环节.吡格列酮通过调节脂质代谢、减少炎症介质释放、改善胰岛素抵抗等途径改善冠心病患者预后.由于胰岛素抵抗是重要的中间环节,故一并讨论.现将关于非糖尿病的冠心病患者,胰岛素抵抗促进冠心病发生发展和吡格列酮改善冠心病患者预后的机制做一综述.“,”The pathogenesis of coronary heart disease is closely related to lipid infiltration,inflammatory injury and endothelial cell dysfunction.Even in non-diabetic patients with coronary heart disease,insulin resistance is common,and participates in the development of coronary heart disease.Pioglitazone improves the clinical outcomes of patients with coronary heart disease by regulating lipid metabolism, reducing the release of inflammatory mediators,improving insulin sensitivity.As insulin resistance is an important intermediate link,we will discuss it in this review at the same time.This current review focuses on non-diabetic patients with coronary heart disease,analyzes how insulin resistance promotes the development of coronary heart disease and how pioglitazone improves the clinical outcomes of patients with coronary heart disease.